RecruitingNCT05478538

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)

Sponsor

Elephas

Enrollment

200 participants

Start Date

Jan 31, 2023

Study Type

OBSERVATIONAL

Conditions

NSCLC (Non-small Cell Lung Cancer)Metastatic NSCLC - Non-Small Cell Lung Cancer

Summary

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting lung tissue samples from people with advanced (Stage IV) non-small cell lung cancer (NSCLC) to help train a new technology that can analyze live tumor cells in real time. The goal is to develop better diagnostic tools that could eventually guide personalized cancer treatment. **You may be eligible if...** - You are 18 or older - You are suspected of having or have been diagnosed with Stage IV NSCLC (metastatic lung cancer) - You are scheduled to undergo a biopsy as part of your standard care, and can have a few extra tissue samples collected at the same time - You have not yet started first-line treatment (if newly diagnosed) **You may NOT be eligible if...** - Your doctor determines it is not safe to collect the additional biopsy samples - You have already started your next line of treatment (for those with a prior diagnosis) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURECore Needle, Forceps, or Punch Biopsy

Subjects must be clinically able, at investigator discretion, to undergo additional core needle, forceps, or punch biopsy during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.